Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
Pliant Therapeutics, Inc. PLRX
$0.78
▼ -2.33%
($-0.02)
🧊 52W Low
⬇️ Below Yest. Low
Open
$0.83
Prev Close
$0.80
Day Range
$0.77 – $0.83
52W Range
$0.79 – $1.82
Market Cap
$49.51M
Beta
1.40
EPS (TTM)
$-2.43
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-06-03 |
| Shares Out. | 61,920,000 |
| Website | pliantrx.com/ ↗ |
| Phone | 16504816770 |
| Employees | 49 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$22.4M |
| Free Cash Flow | -$70.9M |
| Total Assets | $189.9M |
| Total Liabilities | $43.0M |
| Equity | $146.9M |
About Pliant Therapeutics, Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Pliant Therapeutics, Inc. is a publicly traded company under the ticker symbol PLRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-11-01)